Director / Participación PDMR
EKF Diagnóstico Holdings plc
("EKF", la "Compañía" o el "Grupo")
Relaciones con PDMR / Director
EKF Diagnóstico Holdings plc (AIM: EKF), the?AIM-listed global diagnostics business, announces that the Board of EKF has been informed that on Friday 22 March 2024, certain funds connected to Christopher Mills, Non-Executive Director, purchased a total of 100,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 25.78 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 132,350,000 Ordinary Shares, representing approximately 29.169% of the total voting rights over the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.
Notificación y divulgación pública de transacciones por parte de personas que desempeñan responsabilidades de gestión y personas estrechamente relacionadas con ellas.
1
| Detalles de la persona que cumple con las responsabilidades de gestión / persona estrechamente asociada
| ||||
a)
| Nombre
|
Harwood Capital LLP and Harwood Capital Management (Gibraltar) Ltd, (the "Investment Managers") | |||
2
| Razón de la notificación
| ||||
a)
| Posición / estado
| Christopher Mills is the Non-Executive Director of the issuer and Chief Executive of the Investment Managers | |||
b)
| Notificación inicial / Enmienda
| Notificación inicial | |||
3
| Datos del emisor, participante en el mercado de derechos de emisión, plataforma de subastas, subastador o supervisor de subastas
| ||||
a)
| Nombre
| EKF Diagnóstico Holdings plc | |||
b)
| LEY
| 213800DXTF3EAUK1AR05
| |||
4
| Detalles de la (s) transacción (es): sección que se repetirá para (i) cada tipo de instrumento; (ii) cada tipo de transacción; (iii) cada fecha; y (iv) cada lugar donde se han realizado transacciones
| ||||
a)
| Descripción del instrumento financiero, tipo de instrumento | Acciones ordinarias de 1 peniques cada una | |||
Código de identificación | GB0031509804
| ||||
b)
| Naturaleza de la transacción
| Compra de acciones ordinarias | |||
c)
| Precio (s) y volumen (es) | ||||
Precios) | Volumen (s) | ||||
25.78p | 100,000 | ||||
d)
| Información agregada | ||||
- Volumen agregado | N / A transacción única | ||||
- Precio | |||||
e)
| Fecha de la transacción
| 22 de marzo de 2024 | |||
f)
| Lugar de la transacción
| Bolsa de Valores de Londres, AIMX | |||
EKF Diagnóstico Holdings plc | www.ekfdiagnostics.com | ||
Julian Baines, presidente ejecutivo | Tel: 44 0 29 2071 0570 | ||
Singer Capital Markets (Asesor nominado y Broker) | Tel.: +44 (0) 20 7496 3000 | ||
Aubrey Powell/Oliver Platts | |||
Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 o GME@dhr-rgv.com | ||
Paul McManus/Alice Woodings | Móvil: +44 (0) 7980 / +541 (893) 44 | ||
About EKF Life Sciences
EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical, and industrial applications.
EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.
Utilising its unique technical expertise, the EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.
EKF Life Sciences has two state-of-the-art GMP manufacturing facilities, located within close proximity, in Elkhart and South Bend Indiana, one the US's major life sciences and industrial hotspots. It operates to the highest regulatory standards under cGMP principles, FDA certification and ISO 13485 Quality Program. The facilities include bioreactors ranging from 5L to 14,500L, enabling it to offer an end-to-end service from bench/proof-of-concept through to full scale commercial production, providing its customers with desired yields, precision at scale and cost-efficiency.
EKF Lifesciences is also one of the market leaders for the supply of ?-HB, a reagent used to detect ketones for patients suffering from diabetic ketoacidosis, as well as many other clinical applications.
Acerca de EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF es una empresa de diagnóstico global que cotiza en AIM y se centra en:
· Punto de cuidado analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges.
· Ciencias de la vida services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services.
EKF tiene su sede en Penarth (cerca de Cardiff) y opera cinco sitios de fabricación en los EE. UU. y Alemania, vendiendo en más de 120 países en todo el mundo.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.